Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum - Summary - MDSpire

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum

  • By

  • Jaime Fernández Arias

  • Wagner S Brum

  • Gemma Salvadó

  • Joseph Therriault

  • Stijn Servaes

  • Yi-Ting Wang

  • Etienne Aumont

  • Nesrine Rahmouni

  • Arthur C Macedo

  • Kely Monica Quispialaya

  • Seyyed Ali Hosseini

  • Peter Kunach

  • Wan Lu Jia

  • Tevy Chan

  • Lydia Trudel

  • Brandon Hall

  • Yanseng Zheng

  • Sejal Mohapatra

  • Sulantha S Mathotaarachchi

  • Paolo Vitali

  • Cécile Tissot

  • Gleb Bezgin

  • Yasser Iturria-Medina

  • Nicholas J Ashton

  • Andréa Lessa Benedet

  • Thomas K Karikari

  • Gallen Triana-Baltzer

  • Jesse M Klostranec

  • Hartmuth C Kolb

  • Eduardo R Zimmer

  • Shorena Janelidze

  • Niklas Mattsson-Carlgren

  • Erik Stomrud

  • Sebastian Palmqvist

  • Henrik Zetterberg

  • Kaj Blennow

  • Tharick Pascoal

  • Maxime Montembeault

  • Oskar Hansson

  • Pedro Rosa-Neto

  • January 29, 2025

  • 0 min

Share

Objective:

To investigate the relationship between plasma p-tau biomarkers and cognitive performance, specifically focusing on memory and executive function, in individuals with varying cognitive statuses and amyloid-β positivity.

Key Findings:
  • Plasma p-tau217 showed a stronger association with cognitive performance than p-tau181 and p-tau231, particularly for memory scores, with area under the curve values indicating high diagnostic accuracy.
  • Plasma p-tau217 outperformed other biomarkers in identifying memory impairment with area under the curve values of 0.86 in both cohorts, suggesting its potential as a reliable diagnostic tool.
  • Cognitively impaired individuals exhibited strong associations across cognitive scores with p-tau217, highlighting its relevance in clinical assessments.
  • Subtle memory deficits were present in A+T1+T2− participants for p-tau217 and p-tau181, indicating early cognitive changes.
Interpretation:

Plasma p-tau217 is a promising biomarker for identifying memory deficits in Alzheimer’s disease, even in individuals without significant tau accumulation in the neocortex.

Limitations:
  • Cross-sectional design limits causal inferences and understanding of temporal relationships.
  • Sample size may affect generalizability of findings, particularly in diverse populations.
Conclusion:

Plasma p-tau217 is a valuable biomarker for detecting cognitive impairment related to Alzheimer’s disease, particularly in memory domains, and may enhance early diagnosis and intervention strategies.

Original Source(s)

Plasma phosphorylated tau217 strongly associates with memory deficits in the Alzheimer’s disease spectrum

  • by Jaime Fernández Arias, Wagner S Brum, Gemma Salvadó, Joseph Therriault, Stijn Servaes, Yi-Ting Wang, Etienne Aumont, Nesrine Rahmouni, Arthur C Macedo, Kely Monica Quispialaya, Seyyed Ali Hosseini, Peter Kunach, Wan Lu Jia, Tevy Chan, Lydia Trudel, Brandon Hall, Yanseng Zheng, Sejal Mohapatra, Sulantha S Mathotaarachchi, Paolo Vitali, Cécile Tissot, Gleb Bezgin, Yasser Iturria-Medina, Nicholas J Ashton, Andréa Lessa Benedet, Thomas K Karikari, Gallen Triana-Baltzer, Jesse M Klostranec, Hartmuth C Kolb, Eduardo R Zimmer, Shorena Janelidze, Niklas Mattsson-Carlgren, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Kaj Blennow, Tharick Pascoal, Maxime Montembeault, Oskar Hansson, Pedro Rosa-Neto

  • January 29, 2025

Related Content

Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals

Observing and treating pain in people living with dementia in long-term care facilities

Housing Insecurity, Incident Geriatric Conditions, and Mortality in Community-Living Older Persons